Publication: Home-based chemotherapy for stage III colon cancer patients in Thailand: Cost-utility and budget impact analyses
Issued Date
2020-01-01
Resource Type
ISSN
20457634
Other identifier(s)
2-s2.0-85098290369
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer Medicine. (2020)
Suggested Citation
Nattanichcha Kulthanachairojana, Phichai Chansriwong, Nintita Sripaiboonkij Thokanit, Suwannee Sirilerttrakul, Nopakan Wannakansophon, Suthira Taychakhoonavudh Home-based chemotherapy for stage III colon cancer patients in Thailand: Cost-utility and budget impact analyses. Cancer Medicine. (2020). doi:10.1002/cam4.3690 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60884
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Home-based chemotherapy for stage III colon cancer patients in Thailand: Cost-utility and budget impact analyses
Other Contributor(s)
Abstract
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Home-based chemotherapy (HC) is a new treatment alternative to hospital-based chemotherapy treatment (IP) and is administered via portable intravenous pumps at the patient's home. HC reduces the demand for inpatient bed capacity in hospitals and reduces the cost of an infusion. This study takes a societal perspective while conducting the cost-utility and budget impact analyses (BIA) of HC and IP with an mFOLFOX6 regimen on patients with stage III colon cancer. We conducted a cost-utility analysis with a 6-month time horizon. The parameter inputs for the model were gathered from a retrospective cohort study on patients diagnosed with stage III colon cancer at Ramathibodi Hospital, Bangkok. The resource usage of HC and IP was determined based on medical records. The per-unit direct medical, home health service, and adverse events (AE) management costs were gathered from the standard cost list. The health outcome of treatment was measured in terms of quality-adjusted life years. Disutility related to AE was calculated. We conducted a sensitivity analysis for the uncertainty results and performed BIA based on the societal perspective on a 1-year time horizon. HC provided a cost-saving of $1,513.37 per patient for the period of treatment. Thus, assuming 526 patients per year, the use of HC could achieve a cumulative annual cost-saving of $828,436. HC is a cost-saving strategy compared to IP for stage III colon cancer treatment. We recommend that the service reimbursement should include national standardization in chemotherapy regimens as well as practice guidelines and protocols to prevent serious AEs.